Microba Life Sciences Limited (FRA:F3Y)

Market Cap	16.27M -38.7%
Revenue (ttm)	8.94M -5.8%
Net Income	-12.55M
EPS	-0.02
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	2,400
Open	0.0185
Previous Close	0.0195
Day's Range	0.0185 - 0.0185
52-Week Range	0.0175 - 0.0525
Beta	n/a
Analysts	n/a
Price Target	n/a
Est. Earnings	Oct 27, 2026

About Microba Life Sciences

Microba Life Sciences Limited provides microbiome testing, supplements, and analysis services in Australia, Europe, New Zealand, the United Arab Emirates, the United Kingdom, the United States, Asia, and Ireland. It operates through, Testing Services and Supplements, and Research and Development segments. The company also develops pathology, therapeutics, and diagnostics services based on the human gut microbiome. In addition, it offers MetaPanel, a metagenomic test for pathogen detection; microba microbiome explorer; research testing services;...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 2017
• Country: Australia
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: F3Y

Financial Performance

In fiscal year 2026, Microba Life Sciences's revenue was 14.76 million, a decrease of -5.81% compared to the previous year's 15.67 million. Losses were -20.72 million, 38.7% more than in 2025.

Financial numbers in AUD

Data Sources: S&P Global Market Intelligence and Twelve Data

Fundamental and historical data is provided by S&P Global Market Intelligence. Delayed stock pricing data is provided by Twelve Data.

Last checked:

Oct 26, 2026

Data Sources Report a data error